US EditionProkaryotics Licenses Gram-Negative Antibiotic Potentiator From Northern Antibiotics
UNION COUNTY, NEW JERSEY, JUN 26 – The licensing agreement allows Prokaryotics to develop NAB741, which increases Gram-negative bacterial membrane permeability and has completed Phase 1 trials, enhancing antibiotic effectiveness.
Summary by pharmtech.com
2 Articles
2 Articles
All
Left
1
Center
1
Right
Prokaryotics Announces Licensing Agreement with Northern Antibiotics for Novel Gram-negative Antibiotic Potentiator
UNION, N.J., June 26, 2025 /PRNewswire/ -- Prokaryotics Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs, announced today that it has entered into a licensing agreement with Northern Antibiotics on June 4, 2025.
Coverage Details
Total News Sources2
Leaning Left1Leaning Right0Center1Last UpdatedBias Distribution50% Left, 50% Center
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
50% Center
L 50%
C 50%
Factuality
To view factuality data please Upgrade to Premium
